Noticias y vídeos - ITEOS THERAPEUTICS INC. - Inglés - Página 2

- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant’s Phase 2 A2A-005 and EOS-984’s Phase 1 trial - EOS-984 preclinical data demonstrating novel mechanism of action in the adenosine pathway anticipated in second quarter of 2024 - Cash balance and investment balance of $644.9 million as of...

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 03, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 10, 2024 at 3:00 p.m. PST...

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35 th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET. A live webcast of the event will be...

- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose escalation arm in TIG-007 Phase 2 trial in multiple myeloma - Completed enrollment of first dose cohort in Phase 1 trial of EOS-984 - Cash balance and investment balance of $644.9 million as of September 30, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones...

WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September: H.C. Wainwright 25 th Annual Global Investment Conference Format: Fireside chat and one-on-one investor meetings Date:...

– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated enrollment in Phase 1 trial of EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway – Cash balance and investment balance of $677.5 million as of June 30, 2023 expected to provide runway into 2026 through a number of impactful milestones across portfolio WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 08, 2023 (GLOBE...

– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of action in the adenosine pathway, EOS-984, is expected to enter clinical studies mid-year – Cash balance and investment balance of $706.6MM as of March 31, 2023, expected to provide runway into 2026 through a number of impactful milestones across portfolio WATERTOWN, Mass. and GOSSELIES, Belgium, May 10,...

- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies in mid-2023 - Cash and investment balance of $731.4MM as of December 31, 2022 , expected to provide runway into 2026 WATERTOWN, Mass. and GOSSELIES, Belgium,...

WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference being held virtually on Tuesday, February 14, 2023 at 10:00 a.m. EST. A live webcast of...

- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - Eleven clinical trials planned or ongoing against multiple tumor types, across three pipeline programs - EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies mid-2023 - Cash balance of $752MM as of September 30, 2022, expected to provide runway into 2026 through...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST (11:15 a.m. EST)....

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Piper Sandler 34 th Annual Healthcare Conference in New York City on Tuesday, November 29, 2022 at...

– Initiated a randomized Phase 2 trial evaluating anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and GSK’s anti-PD-1 Jemperli (dostarlimab) in first line, metastatic non-small cell lung cancer – Phase 2 trials with novel combinations underway for both monoclonal anti-TIGIT antibody, EOS-448, and adenosine A 2A receptor antagonist, inupadenant – Cash balance of $752MM as of September 30, 2022, expected to provide runway into 2026 to support differentiated clinical programs for EOS-448...

- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A, and GSK’s anti-PD-1 Jemperli (dostarlimab) - Enrolling patients with non-small cell lung cancer in a randomized Phase 2 trial evaluating the combination of inupadenant, an A 2A receptor antagonist, with chemotherapy - Cash balance of $792MM as of June 30, 2022, expected to provide runway into 2026 to support differentiated clinical...

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs Wide Open – Opportunities and...

Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with BMS’s novel CELMoD agent, iberdomide. Enrolling patients in the biomarker cohort in an ongoing clinical trial of inupadenant, an A 2A receptor antagonist, as a monotherapy in patients with solid tumors expressing high levels of A 2A to explore observed relationship between A 2A levels and clinical benefit Presented updated preclinical and...

Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibody In preclinical studies and in blood samples from patients with advanced cancers, treatment with EOS-448 results in a reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions WATERTOWN, Mass. and GOSSELIES,...

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab -gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed clinical trials with this combination - Initiating trials combining EOS-448 and Jemperli in triplet regimens with inupadenant and GSK's investigational anti-CD96 antibody, GSK6097608 - Advanced clinical development of inupadenant, EOS-850, an A 2A receptor antagonist, start of...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences in February: 11 th Annual SVB Leerink Global Healthcare Conference...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today provided a clinical development plan for its anti-TIGIT monoclonal antibody, EOS-448, and its A 2A receptor antagonist, inupadenant. iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief...